Mirabegron

Product introduction:

Mirabellon was the first drug used to treat overactive bladder β 3 adrenoceptor agonists, whose successful listing filled the gap β Adrenoceptor agonists are blank in the treatment of overactive bladder.

Synonymous	2-AMino-N-[4-[2-[[(2R)-2-hydroxy-2-phenyl-ethyl]aMino]-ethyl]phenyl]-4-thiazoleacetaMide；(2R)-2-(2-AMinothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)aMino]ethyl]acetic Acid Anilide
Structure
CAS	223673-61-8
Molecular Formula	C₂₁H₂₄N₄O₂S
Molecular Weight	396.51
Appearance	White to light yellow powder
Packing	25kg cardboard barrel
Uses	It is used to treat urgent urination, frequent urination and urinary incontinence caused by overactive bladder
Storage	Dark and dry

Pharmacological action:

Mirabellon mainly acts on β 3 receptor relaxes bladder detrusor and increases its stability. Three species were found in human detrusor cells and urethral epithelial cells β Receptor subtype（ β 1. B2 and β 3)， β The mRNA of 3 receptor is mainly expressed in human urinary smooth muscle cells, accounting for 40% of bladder tissue β 97% of receptor mRNA. β The expression of receptor mRNA and the function of its signal pathway suggest β 3 receptor plays a mainstay role in normal and diseased bladder.

Properties

Mirabelon tablets, developed by Estelle pharmaceutical company of Japan, were listed in Japan on September 16, 2011 and approved by the US Food and Drug Administration (FDA) on June 28, 2012 for the treatment of adult overactive bladder (OAB). Mirabelon was the first to be used to treat overactive bladder β 3. Adrenoceptor agonists, whose successful marketing fills the gap β There is a blank of adrenoceptor agonists in the treatment of overactive bladder.

CAS No.

223673-61-8

Formula

C21H24N4O2S

Molecular Mass

396.50600

Exact Mass

396.16200

PSA

128.51000

Logp

3.81730